EVis Bioscience raises EUR 740,000

ETH Zurich spin-off EVis Bioscience is developing an RNA delivery platform based on extracellular vesicles. It has raised EUR 740,000 in pre-seed funding through the Capital Cell platform to strengthen its team and preclinical programmes.

Announced on
Round
Pre-seed
Amount
EUR 740,000
Location
Zurich
Sector
Biotech & life sciences

Investors

The investors were not named in the announcement.

Preparing a similar round?

The diagnostic shows you the instruments and investors that fit your stage.

Start the diagnostic